ReSolve has successfully facilitated the sale of Safeguard Biosystems Holdings Limited's assets to Safeguard DX Limited, allowing for continued development in sepsis diagnostics.

Target Information

Safeguard Biosystems Holdings Limited, commonly referred to as Safeguard Biosystems, is a US-based medical testing start-up specializing in innovative solutions for sepsis diagnostics. The company aims to eliminate the traditional culture step in sepsis testing by utilizing advanced molecular diagnostics and DNA sequencing technologies. This approach is designed to significantly enhance both the speed and accuracy of diagnosing this life-threatening condition.

Safeguard’s core product has the potential to decrease the time and cost associated with sepsis care by up to 93% when compared to conventional treatment options. The company holds 39 global patents and has an additional 92 patents pending across four different patent families, securing a strong intellectual property position. With approximately 50 million cases of sepsis reported globally each year, the blood culture market is projected to be worth £4.8 billion.

Industry Overview

The medical diagnostics industry in the United States is rapidly evolving, particularly in the area of infectious disease testing. As the prevalence of conditions such as sepsis continues to rise, the demand for more effi